ADAM17
MOLECULAR TARGETADAM metallopeptidase domain 17
ADAM17 (ADAM metallopeptidase domain 17) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting ADAM17
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | cgs 27023a | 3.76 | 42 |
| 2 | marimastat | 3.47 | 31 |
| 3 | ilomastat | 3.40 | 29 |
| 4 | prinomastat | 2.94 | 18 |
| 5 | cts 1027 | 2.64 | 13 |
| 6 | batimastat | 2.48 | 11 |
| 7 | ro 319790 | 1.79 | 5 |
| 8 | Bisphenol A-Glycidyl Methacrylate | 1.10 | 2 |
| 9 | Kaempferols | 0.69 | 1 |
| 10 | Prednisolone | 0.69 | 1 |
About ADAM17 as a Drug Target
ADAM17 (ADAM metallopeptidase domain 17) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented ADAM17 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
ADAM17 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.